Magnifying glass focusing on number 2026 with target icon on yellow background
Biotech

Despite headwinds, biotech industry charges forward behind M&A

Biotech’s effervescent activity has allowed it to overcome headwinds and sustain momentum, as the volume and value of M&A deals continue to increase.
Kevin Dunleavy Jun 9, 2026 12:41pm
rollercoaster ride theme park scary crazy

Parabilis ups planned IPO haul to record-setting $637M

Jun 9, 2026 10:22am
FranchiseKeyvisualsOncologyLevel2Digital-nonepng

Could engaging the immune system improve AML outcomes?

Brought to you by Ipsen
AlzeCure

Lilly licenses AlzeCure Alzheimer’s asset for $1B biobucks

Jun 9, 2026 10:16am
AZ

ADA: AZ’s oral GLP-1 shows ‘competitive efficacy’ in phase 2

Jun 9, 2026 9:48am
Darts failing to hit bullseye

Bial bails after Parkinson’s fail, axing asset over phase 2 miss

Jun 9, 2026 5:22am
More News

GSK inks $10.6B Nuvalent buyout to challenge Roche and Pfizer

Jun 9, 2026 4:41am

Fierce Biotech Fundraising Tracker '26: City, Ona & more

Jun 8, 2026 4:00pm

City lays foundation for RNAi renaissance with nearly $100M

Jun 8, 2026 4:00pm
Fierce Pharma

Eli Lilly is the ‘clear winner’ from ADA, RBC analyst says

Jun 8, 2026 3:12pm